Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pathologic Complete Response 1

Interventions

Magnetic Resonance Spectroscopy 287 Specimen Handling 285 pembrolizumab 258 Cyclophosphamide 237 Radiotherapy 233 Nivolumab 187 Cisplatin 174 Biopsy 170 Carboplatin 155 Radiosurgery 142 fludarabine 131 Blood Specimen Collection 130 Surveys and Questionnaires 120 Gemcitabine 120 Paclitaxel 115 venetoclax 114 Standard of Care 112 Dexamethasone 105 Bevacizumab 98 Radiation 97 Rituximab 92 Oxaliplatin 89 Cytarabine 88 Capecitabine 88 Drug Therapy 86 Ipilimumab 85 Doxorubicin 83 durvalumab 81 atezolizumab 76 fludarabine phosphate 73

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × tegafur-gimeracil-oteracil × 90 days × Clear all

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡